Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.
Saved in:
| Title: | Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. |
|---|---|
| Authors: | Uhlik M; OncXerna Therapeutics, Inc., Waltham, MA, United States., Pointing D; Genialis, Inc., Boston, MA, United States., Iyer S; OncXerna Therapeutics, Inc., Waltham, MA, United States., Ausec L; Genialis, Inc., Boston, MA, United States., Štajdohar M; Genialis, Inc., Boston, MA, United States., Cvitkovič R; Genialis, Inc., Boston, MA, United States., Žganec M; Genialis, Inc., Boston, MA, United States., Culm K; OncXerna Therapeutics, Inc., Waltham, MA, United States., Santos VC; OncXerna Therapeutics, Inc., Waltham, MA, United States., Pytowski B; OncXerna Therapeutics, Inc., Waltham, MA, United States., Malafa M; Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States., Liu H; Checkmate Pharmaceuticals, Inc., Cambridge, MA, United States., Krieg AM; Checkmate Pharmaceuticals, Inc., Cambridge, MA, United States., Lee J; Department of Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea., Rosengarten R; Genialis, Inc., Boston, MA, United States., Benjamin L; OncXerna Therapeutics, Inc., Waltham, MA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2023 May 12; Vol. 13, pp. 1158345. Date of Electronic Publication: 2023 May 12 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
